Owkin has signed a three-year licensing deal with AstraZeneca to build custom AI agents using its K Pro platform. The agreement expands on previous work between the companies and signals growing pharmaceutical industry adoption of AI-powered research tools.
The partnership matters because it shows how major drug companies are moving beyond basic AI experiments toward integrated systems that support complex business decisions. AstraZeneca will get AI agents designed specifically for competitive intelligence and drug development choices, potentially speeding up research timelines in an industry where new medicines can take over a decade to develop.
Custom AI agents for drug discovery
Under the agreement, Owkin will develop AI agents that integrate directly with AstraZeneca’s existing IT systems and decision-making processes. The agents will help AstraZeneca teams access data-driven insights for competitive intelligence questions, reducing the need for manual analysis.
The K Pro platform combines multiple types of biological data with specialized AI designed for pharmaceutical research. Thomas Clozel, Owkin’s CEO and co-founder, said the company believes “the future of the pharmaceutical industry is agentic” and that their infrastructure allows them to build complex agents for pharmaceutical partners.
Building on previous cancer research success
This new deal builds on earlier collaboration between the companies. They previously worked together on an AI solution called BRCAura for breast cancer screening, which can identify patients unlikely to carry harmful genetic mutations.
Results published at the ESMO conference showed the BRCAura system could rule out about 40% of patients who don’t have the target genetic mutations, while maintaining 93% accuracy in detecting those who do have them. This type of pre-screening could help doctors focus genetic testing on patients most likely to benefit.
Industry trend toward specialized AI
The AstraZeneca partnership reflects a broader shift in how pharmaceutical companies approach AI adoption. Rather than using general-purpose AI tools, companies are investing in specialized systems trained on biological and medical data.
Owkin positions itself as an “agentic AI company” focused on what it calls “Biological Artificial Superintelligence.” The company has built a network of patient data and AI tools specifically designed for pharmaceutical research challenges that have proven difficult for human researchers alone.
The cancer screening work continues through Waiv, a recent spin-off of Owkin’s diagnostic division, while Owkin focuses on its core platform for drug discovery and development.